AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05996835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIN816 70 mg lyophilisate powder
Description: Immunotherapy Recombinant human CD39 enzyme
Study NCT06256952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social inclusion (Cyberball task)
Description: Social inclusion will be assessed using the cyberball paradigm: subjects will play an online game tossing a ball to each other with two more virtual co-players. Using a cover story, we make subjects believe that the co-players really exist and that they play a live online game. During social inclusion, ball tosses will be balanced between all three players.
Study NCT06564298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg iv.gtt d1, every 21 days
Study NCT06564298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab 10mg/kg iv.gtt d1, every 21 days
Study NCT06564298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX/XELOX
Description: SOX: Oxaliplatin 130mg/m2 iv.gtt d1, every 21 days and S-1 40mg/m2 po bid d1-14, every 21 days XELOX: Oxaliplatin 130mg/m2 iv.gtt d1, every 21 days and Capecitabine 1000mg/m2 po bid d1-14, every 21 days
Study NCT06170476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542-60μg
Description: HSK21542 injection of 60 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
Study NCT06170476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542-120μg
Description: HSK21542 injection of 120 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
Study NCT06170476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542-180μg
Description: HSK21542 injection of 180 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
Study NCT06170476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
Study NCT06405113 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy
Description: Participants received Fecal Microbiota Transplantation (FMT) combined with (Oxaliplatin + S-1)+Sintilimab
Study NCT06405113 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy
Description: Participants received Fecal Microbiota Transplantation (FMT) combined with (Oxaliplatin + S-1)+Sintilimab
Study NCT06575010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: 20 mL Liposomal bupivacaine (Exparel) will be given in the shoulder block prior to surgery
Study NCT06575010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.5% Inj
Description: 0.75% bupivacaine will be given in the shoulder block prior to surgery
Study NCT06575010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 10 mg Dexamethasone will be given in the shoulder block prior to surgery
Study NCT05996835 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sterile saline solution
Study NCT06291584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: In the exercise program, the first 5 minutes are for heating, and the last 5 minutes are for cooling. In the exercise program, which is planned to last 40 minutes in total, respiratory exercises will be applied to heating and cooling peryotes. At the end of respiratory exercises, resistance exercise training will be started. Elastic resistant bands (Therand) will be used in resistant exercise training that will last for 30 minutes. The participants will be started to work with the resistance that they can do 10 again but cannot reach 14 repetitions. Elastic resistant bands are shoulder flexion, shoulder extension, shoulder ablution, shoulder horizontal abduction, elbow extension, hip ablution, hip flexion, hip extrudy, squat, and cat-decrease. These exercises will be held once a week, 10 repetitions, 2 sets, for 8 weeks.
Study NCT06606899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 3 MG
Description: Oral syrup melatonin 3 mg
Study NCT06606899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloral Hydrate
Description: Oral chloral hydrate (50 mg/kg, maximum 2 g)
Study NCT06606899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Inhalational Sevoflurane
Study NCT06667960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK06
Description: Biparatopic anti-5T4 antibody
Study NCT06670950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYT-510
Description: Oral formulation A fasted
Study NCT06670950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYT-510
Description: Oral formulation B fasted
Study NCT06670950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYT-510
Description: Oral formulation A fed
Study NCT06670950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral formulation
Study NCT04643769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIN1001
Description: Oral tablet - ORIN1001
Study NCT04643769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet - placebo
Study NCT06613243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine 0.2 mg/kg
Description: Esketamine 0.2 mg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
Study NCT06613243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 0.2 mg/kg + dexmedetomidine 0.1 µg/kg
Description: A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.1 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
Study NCT06613243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 0.2 mg/kg + dexmedetomidine 0.15 µg/kg
Description: A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.15 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
Study NCT06613243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 0.2 mg/kg + dexmedetomidine 0.2 µg/kg
Description: A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.2 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
Study NCT04923776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: The dosage for this drug is area under the curve (AUC) 5 mg/ml/min intravenous, Day 1, every 21 days for 4 cycles. This is standard of care.
Study NCT04923776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: The dosage for this drug is 100 mg/m2 Intravenous, Days 1-3, every 21 days for 4 cycles. This is standard of care.
Study NCT04923776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: The dosage for this drug is 1200 mg Intravenous, Day 1, every 21 days until disease progression. This is standard of care.
Study NCT04923776 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: This radiotherapy is given within +/-3 days of cycle 2, 10 Gy 3 doses on alternating days. This is not standard of care and considered interventional.
Study NCT06409741 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary sphincterotomy
Description: ERCP for biliary sphincterotomy will be performed during index admission for acute pancreatitis, prior to discharge or up till one month from discharge.~The procedure will be performed after at least 6 hours of fasting during the index admission, by endoscopists in charge of performing ERCP as usual in the collaborating centers under sedation controlled by endoscopists or anesthesia according to the usual practice of the Endoscopy Unit of each collaborating center.~For ERCP biliary cannulation, the usual techniques available in each center will be used, including advanced cannulation techniques if necessary.~If biliary cannulation is not possible, a new ERCP attempt will be performed within a maximum of one month. If biliary cannulation is still not achieved, it will be it will be counted as a technical failure, maintaining the established clinical follow-up.
Study NCT06528990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Intervention
Description: This includes the following key components: 1) assignment to a peer ostomate; 2) ostomy self-management skills building delivered through group telehealth sessions and led by trained ostomy nurses and peer ostomates; 3) intervention resource manual.
Study NCT06528990 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: standard of care, where patients and family caregivers are managed by the oncology care team. Care may include clinic visits for follow-up, cancer directed treatments, referrals to other medical specialties as needed, and institutional ostomy nurse support before and after surgery as needed.
Study NCT06669559 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DROM-Test
Description: DROM test: a tool for assessing the ability to decide on returning home
Study NCT06170814 — intervention group
Intervention type: OTHER
Intervention: Exercise
Description: Exercise will be done for approximately 40 minutes, 3 days a week for 6 weeks. Ramps, obstacle jumping, stairs and tracks will be built to improve walking and balance functions. One group will be given external focus stimuli, the other group will be given internal focus stimuli.
Study NCT05073133 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OAV101
Description: A single Gene Therapy IV infusion at 1.1e14 vector genome (vg)/kg over approximately 60 minutes
Study NCT06478017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Patients will receive 10mg/kg on Day 3 post-transplant (72 hours +/- 12 hours post-transplant)~Day 7 post-transplant (+/- 6 hours)~Day 16 (End of Week 2 after 1st dose of belatacept) post-transplant (+/- 2 days)~Day 30 (End of Week 4 after 1st dose of belatacept) post-transplant (+/- 3 days)~Day 58 (Week 8) post-transplant (+/- 3 days)~Day 86 (Week 12) post-transplant (+/- 3 days)~Patients will receive 5mg/kg Every 28 days (+/- 3 days) thereafter
Study NCT06478017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Prograf (tacrolimus) or tacrolimus generic
Study NCT06478017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Prograf (tacrolimus) or tacrolimus generic
Study NCT06478017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil/Sodium
Description: CellCept (mycophenolate mofetil- MMF), or Myfortic (mycophenolate sodium)
Study NCT06478017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil/Sodium
Description: CellCept (mycophenolate mofetil- MMF), or Myfortic (mycophenolate sodium)
Study NCT06478017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone
Study NCT06478017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone
Study NCT06669143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160 mg bid, po, day 1-21, a maximum of 2 years.
Study NCT06669143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg qd, po, day 1-10, a maximum of 2 years.
Study NCT05628324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: practice muscle activation patterns
Description: practice upper limb muscle activation patterns using EMG-controlled games
Study NCT05628324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: task practice
Description: practice functional upper limb tasks
Study NCT05628324 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: task practice
Description: practice functional upper limb tasks
Study NCT06617897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL511 Fibrinogen concentrate (human)
Description: CSL511 will be prepared in sterile water for injection and administered as an intravenous (IV) infusion.
Study NCT06617897 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprecipitate
Description: Cryoprecipitate will be administered via IV infusion.
Study NCT05155605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Cancer Early Detection Test
Description: Blood collection and multi-cancer early detection testing with return of results.
Study NCT06628921 — intervention group
Intervention type: DRUG
Intervention: Eptinezumab 100 or 300 mg ev
Description: Eptinezumab administered for migraine prevention in patients but with ongoing migraine attacks.
Study NCT05292027 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-dose radiotherapy
Description: On the first and second days of induction chemotherapy, lymph nodes were irradiated with 0.5Gy bid for 4 times.
Study NCT06703216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra (Kineret®)
Description: Pre-emptive Anakinra at the initial onset of CRS.
Study NCT06732180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT-02287
Description: Dose of 13.5 mg/kg/day (plus/minus 2 mg/kg/day based on body weight) to be administered orally once a day for 90 days. Dosage form: powder in sachet (200 mg of GT-02287 per sachet) for reconstitution with a suspending agent
Study NCT06734832 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent enterovirus vaccine (Vero cell), inactivated
Description: Two doses are administered with a one-month interval between each dose.
Study NCT06734832 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Enterovirus Type 71 Vaccine (Vero Cell), Inactivated
Description: Two doses are administered with a one-month interval between each dose.
Study NCT06750523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cord blood sampling
Description: A cord blood sample will be taken at birth for analysis of oxidative stress markers, endocrine disruptors, and microRNAs.
Study NCT06750523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: urine sampling
Description: At one month of age, urine samples will be collected from newborns to analyze oxidative stress markers and endocrine disruptors.
Study NCT06750523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life style questionnaire
Description: At the time of enrollment, mothers will complete a specialized questionnaire designed to assess potential exposure to endocrine disruptors (EDCs) through diet, clothing, and the use of cosmetics and detergents.
Study NCT06702657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon dilatation and/or stenting
Description: balloon dilatation and/or stenting immediately after randomization
Study NCT06702657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medication
Description: medication after randomisation, mechanical thrombectomy again if necessary, avoiding balloon dilatation and/or stenting.
Study NCT06750978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-reflection
Description: Participants will be guided to identify goals of daily PSU reduction. o Participants will be guided to actively review their smartphone usage data each day.
Study NCT06750978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-reflection + Alternative activity engagement
Description: Participants will be guided to identify goals of daily PSU reduction and actively review their smartphone usage data each day. Participants will be guided to develop a plan for alternative activity engagement and confirm their engagement in the alternative activities as planned.
Study NCT06750978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-reflection + Contingency management
Description: Participants will be guided to identify goals of daily PSU reduction and actively review their smartphone usage data each day. Participants will receive an incentive ($8) if they meet the daily PSU reduction goal.
Study NCT06755359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: Radioactive sources named Alpha DaRT sources: Ra - 224 coated onto stainless steel tubes inserted into the tumor.
Study NCT06752265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peran sadar application
Description: The PERAN SADAR application is an android-based SACA prevention application containing material related to SACA prevention which is given in a series for nine days using multimedia video stories and songs, documents, and tiktok in an attractive package, so that it attracts someone's interest in listening to the contents of the message. Social media applications are educational methods that are popular with all ages
Study NCT06751797 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05340556 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample of 12 ml EDTA plasma.
Study NCT05340556 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Swap test
Description: receive swab tests for collecting cells from the oral mucosa
Study NCT06168955 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: skin biopsy
Description: skin biopsy for cell culture and N-homocysteinylation study
Study NCT06168955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: skin biopsy for cell culture and N-homocysteinylation study
Study NCT04948190 — intervention group
Intervention type: BEHAVIORAL
Intervention: Testing with medical detection dogs
Description: Participants will be screened by medical detection dogs. In phase 2, participants may be asked to wear clothing samples collected in phase 1, as part of dog training procedures. In subsequent study parts, participants will wear their own clothing.
Study NCT06752577 — intervention group
Intervention type: DRUG
Intervention: Allogeneic, vertebral bone marrow-derived mesenchymal stem cells (MSC)
Description: Single intravenous infusion of 200x10\^6 cells delivered systemically through a peripheral IV (over 15 minutes to 2 hours)
Study NCT06753981 — intervention group
Intervention type: DRUG
Intervention: Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs
Description: Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs Including macitentan sildenafil/tadalafil or riociguat selexipag/epoprostenol.
Study NCT06753721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin liposome combined with CapOX and Bevacizumab
Description: Bevacizumab (7.5 mg/kg, IV, Day 1) + Oxaliplatin (130 mg/m², IV, Day 1) + Capecitabine (1000 mg/m², oral, twice daily, for 14 days) + Doxorubicin liposome (20 mg/m², IV, Day 1), repeated every 3 weeks.
Study NCT06753643 — intervention group
Intervention type: OTHER
Intervention: The IMPACTFrail programme
Description: The IMPACTFrail programme
Study NCT06751992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conversion to extended-release tacrolimus
Description: Conversion from immediate-release tacrolimus (Prograf) to extended-release tacrolimus (Envarsus XR) as a part of the maintenance immunosuppressive treatment
Study NCT06751992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of immediate-release tacrolimus
Description: Continuing immediate-release tacrolimus (Prograf) as a part of the maintenance immunosuppressive treatment
Study NCT06752967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein liquid test meal
Description: High protein liquid test meal consisting of whey protein, water and sugar-free coadial mix for flavour.
Study NCT06752967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High carbohydrate liquid test meal
Description: High carbohydrate liquid test meal consisting of sucrose, water and sugar-free coadial mix for flavour.
Study NCT04260776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 1: Web-based intervention (MyWebQuit) with 1-way text messages
Description: Participants will receive MyWebQuit (web-based smoking intervention) along with a corresponding 1-way text messages
Study NCT04260776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 1: Web-based intervention (MyWebQuit) with interactive, 2-way text messages
Description: Participants will receive MyWebQuit (web-based smoking intervention) along with corresponding interactive, 2-way text messages
Study NCT06752863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypotensive anesthesia in ear, nose and throat surgeries using labetalol and dexmedetomidine infusions
Description: The study compares the role of Labetalol infusion versus Dexmedetomidine infusion in hypotensive anesthesia in patients having ear, nose and throat surgeries
Study NCT06752616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Dexmedetomidine
Description: Sublingual dexmedetomidine 180 mcg, possible second dose 90 mcg after 2 hrs
Study NCT06752616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal midazolam
Description: Buccal midazolam 10 mg, possible second dose 10 mg after 2 hrs